RECRUITING

The Influence of Chardonnay Marc Intake on Gut and Cardiometabolic Health

Conditions

Cardiovascular Diseases Adiposity Cardiometabolic Syndrome

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Recently a dietary recommendation of 400 - 600 mg/ day has been proposed for the reduced risk of developing cardiovascular disease. Dietary flavanols can be obtained from the intake of foods such as tea, cocoa, wine, berries and apples. Incorporating Chardonnay Marc (the skins and seeds of Chardonnay grapes) into the diet can be an additional source of dietary flavanols. Like other flavanol-rich foods, Chardonnay Marc provides fiber and polysaccharides that may benefit gut health. This study seeks pilot data on the impact of the daily incorporation of Chardonnay Marc powder into the diet on markers of gut and cardiometabolic health.

Official Title

The Influence of Chardonnay Marc Intake on Gut and Cardiometabolic Health

Quick Facts

Study Start:2024-06-01

Study Completion:2025-06-30

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06476795

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:45 Years to 70 Years

Sexes Eligible for Study:FEMALE

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Postmenopausal female, with a cessation of menses for at least 2 years * 45-70 years of age * BMI 31- 49.9 kg/m2 * Fasting triglycerides \> 120 mg/dL * Subject is willing and able to comply with the study protocols and procedures.	* Self-reported use of daily anticoagulation agents including aspirin, NSAIDs * Prescription medications and supplements, except for a 6 month stable dose of thyroid medications * Vegan, Vegetarians, food faddists or those consuming a non-traditional diet * Fruit consumption ≥ 3 cups/day * Vegetable consumption ≥ 4 cups/day * Coffee/tea ≥ 3 cups/day * Dark chocolate ≥ 3 oz/day * Self-reported restriction of physical activity due to a chronic health condition * Self-reported chronic/routine high intensity exercise * Blood pressure ≥ 140/90 mm Hg * Self-reported renal or liver disease * Self-reported heart disease, which includes cardiovascular events and stroke, diabetes * Peripheral artery disease Raynaud's syndrome or disease * Inability to properly place or wear the PAT probes or abnormal measurements on pre-screening PAT * Self-reported cancer within past 5 years * Self-reported gastrointestinal disorders, apart from appendix removal * Unwillingness to stop any supplement use, including herbal, plant or botanical, fish oil, oil supplements six weeks prior to study enrollment. * Indications of substance or alcohol abuse within the last 3 years * All forms of smoking (e.g. vaping, cigarette, cannabis) * Current enrollee in a clinical research study.

Inclusion Criteria

Exclusion Criteria

* Postmenopausal female, with a cessation of menses for at least 2 years
* 45-70 years of age
* BMI 31- 49.9 kg/m2
* Fasting triglycerides \> 120 mg/dL
* Subject is willing and able to comply with the study protocols and procedures.

* Self-reported use of daily anticoagulation agents including aspirin, NSAIDs
* Prescription medications and supplements, except for a 6 month stable dose of thyroid medications
* Vegan, Vegetarians, food faddists or those consuming a non-traditional diet
* Fruit consumption ≥ 3 cups/day
* Vegetable consumption ≥ 4 cups/day
* Coffee/tea ≥ 3 cups/day
* Dark chocolate ≥ 3 oz/day
* Self-reported restriction of physical activity due to a chronic health condition
* Self-reported chronic/routine high intensity exercise
* Blood pressure ≥ 140/90 mm Hg
* Self-reported renal or liver disease
* Self-reported heart disease, which includes cardiovascular events and stroke, diabetes
* Peripheral artery disease Raynaud's syndrome or disease
* Inability to properly place or wear the PAT probes or abnormal measurements on pre-screening PAT
* Self-reported cancer within past 5 years
* Self-reported gastrointestinal disorders, apart from appendix removal
* Unwillingness to stop any supplement use, including herbal, plant or botanical, fish oil, oil supplements six weeks prior to study enrollment.
* Indications of substance or alcohol abuse within the last 3 years
* All forms of smoking (e.g. vaping, cigarette, cannabis)
* Current enrollee in a clinical research study.

Contacts and Locations

Study Contact

Roberta R Holt, PhD

CONTACT

5304005952

rrholt@ucdavis.edu

Study Locations (Sites)

University of California, Davis

Davis, California, 95616

United States

Collaborators and Investigators

Sponsor: University of California, Davis

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-06-01

Study Completion Date2025-06-30

Study Record Updates

Study Start Date2024-06-01

Study Completion Date2025-06-30

Terms related to this study

Additional Relevant MeSH Terms

Cardiovascular Diseases
Adiposity
Cardiometabolic Syndrome